Intensity Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

SHELTON, Conn., June 11, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or the "Company"), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, today announced that it intends to offer to sell shares of its common stock in an underwritten public offering. All of the shares of common stock are to be sold by the Company.
ThinkEquity is acting as sole book-running manager for the offering.
The Company intends to use the net proceeds from the offering for the enrollment of patients and to reach data read out in the INVINCIBLE-4 Study, for the treatment of existing patients enrolled in the INVINCIBLE-3 Study, and for working capital and general corporate purposes.
The securities will be offered and sold pursuant to a shelf registration statement on Form S-3 (File No. 333-280681), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the "SEC") on July 3, 2024 and declared effective on July 11, 2024. The offering will be made only by means of a written prospectus and related prospectus supplement. A preliminary prospectus supplement and accompanying prospectus describing the terms of the offering has been or will be filed with the SEC on its website at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to the offering may also be obtained from the offices of ThinkEquity, 17 State Street, 41st Floor, New York, New York 10004. Before investing in this offering, interested parties should read in their entirety the preliminary prospectus supplement and the accompanying prospectus and the other documents that the Company has filed with the SEC that are incorporated by reference in such preliminary prospectus supplement and the accompanying prospectus, which provide more information about the Company and such offering.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.
About Intensity Therapeutics, Inc:
Intensity is a late-stage clinical biotechnology company whose novel engineered chemistry enables aqueous cytotoxic-containing drug formulations to mix and saturate a tumor's dense, high-fat, pressurized environment following direct intratumoral injection. As a result of the saturation, Intensity's clinical trials have demonstrated the ability of the investigational new drug, INT230-6, to kill tumors and elicit an adaptive immune response within days of injection, representing a new approach to cancer cell death that holds the potential to shift the treatment paradigm and turn many deadly cancers into chronic diseases even for malignancies that do not respond to conventional immunotherapy. Intensity has completed two clinical studies and enrolled over 200 patients using INT230-6: a Phase 1/2 dose escalation study in metastatic cancers including sarcomas (NCT03058289), and a Phase 2 randomized control clinical trial in locally advanced breast cancer (the "INVINCIBLE-2 Study") (NCT04781725) in women without undergoing chemotherapy prior to their surgery. The Company initiated a Phase 3 trial in soft tissue sarcoma (the "INVINCIBLE-3 Study") (NCT06263231), testing INT230-6 as second or third-line monotherapy compared to the standard of care ("SOC") with overall survival as an endpoint. Intensity also initiated a Phase 2 study in collaboration with The Swiss Group for Clinical Cancer Research, SAKK (the "INVINCIBLE-4 Study") (NCT06358573) as part of a Phase 2/3 program evaluating INT230-6 followed by the SOC immunochemotherapy and the SOC alone for patients with presurgical triple-negative breast cancer. Pathological complete response ("pCR") is the endpoint. For more information about Intensity, including publications, papers, and posters about its novel approach to cancer therapeutics, visit www.intensitytherapeutics.com
Forward-Looking Statements
Certain statements in this press release may constitute "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended to date. These statements include, but are not limited to, statements relating to the completion of the public offering on the anticipated terms or at all, the Company's intended use of proceeds from the offering, the Company's expected future plans, cash runway, development activities, projected milestones, business activities or results. When or if used in this communication, the words "may," "could," "should," "anticipate," "believe," "estimate," "expect," "intend," "plan," "predict" and similar expressions and their variants, as they relate to the Company or its management, may identify forward-looking statements. The forward-looking statements contained in this press release are based on management's current expectations and projections about future events. Nevertheless, actual results or events could differ materially from the plans, intentions, and expectations disclosed in, or implied by, the forward-looking statements. These risks and uncertainties, many of which are beyond our control, include: the initiation, timing, progress and results of future preclinical studies and clinical trials and research and development programs; the need to raise additional funding before the Company can expect to generate any revenues from product sales; plans to develop and commercialize product candidates; the timing or likelihood of regulatory filings and approvals; the ability of the Company's research to generate and advance additional product candidates; the implementation of the Company's business model, strategic plans for the Company's business, product candidates and technology; commercialization, marketing and manufacturing capabilities and strategy; the rate and degree of market acceptance and clinical utility of the Company's system; the Company's competitive position; the Company's intellectual property position; developments and projections relating to the Company's competitors and its industry; the Company's ability to maintain and establish collaborations or obtain additional funding; expectations related to the use of cash and cash equivalents and investments; estimates regarding expenses, future revenue, capital requirements and needs for additional financing; the Company may not satisfy the Nasdaq Capital Market's requirements for continued listing and be subject to delisting; and other risks described in the section entitled "Risk Factors" in the Company's preliminary prospectus supplement to be filed with the SEC, the Company's Annual Report on Form 10-K for the year ended December 31, 2024 and in the Company's subsequent SEC filings, which can be obtained on the SEC website at www.sec.gov. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management's current estimates, projections, expectations, and beliefs. The Company does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as required by law.
For Investor Relations Inquiries:
Investor Relations Contact:Justin KulikJustin@coreir.comCORE IR(516) 222-2560
Media Contact:Jules AbrahamCORE IRpr@coreir.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/intensity-therapeutics-inc-announces-proposed-public-offering-of-common-stock-302479508.html
SOURCE Intensity Therapeutics Inc.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Yahoo

37 minutes ago

• Yahoo

Could the "Next Nvidia Stock" Actually Be... Nvidia Stock?

There seems at least a solid probability that Nvidia stock still has not just good or even great but amazing growth potential left. Year-over-year earnings growth solidly in the double-digit percentages and a reasonable stock valuation should be all that's needed to keep Nvidia investors very happy. 10 stocks we like better than Nvidia › Many articles have been written over the last year or so about "the next Nvidia (NASDAQ: NVDA) stock," which refers to a stock that has the potential to post incredibly strong gains over at least the medium term, just like the artificial intelligence (AI) chip leader has done. With the risk of sounding like I've lost my mind, I think there's a good case to be made that "the next Nvidia stock" could actually be Nvidia stock. In other words, there seems at least a solid probability that Nvidia stock still has not just good or even great but amazing growth potential left. Think of it as "Nvidia the superstar stock 2.0." I say "at the risk of sounding like I've lost my mind" because I understand the law of large numbers strongly works against my thesis. This "law" basically means that the larger a company becomes, the more difficult it becomes to continue to grow revenue and earnings at a strong pace on a year-over-year percentage basis. And year-over-year earnings (and cash flow) growth is what largely powers stock prices higher. Nvidia is massive. It has a market cap of $3.55 trillion, as of June 18, making it the world's second most valuable publicly traded company, trailing Microsoft by just a sliver. Moreover, Nvidia management expects the company to generate revenue of $45 billion in its fiscal second quarter, which equates to an annual revenue run rate of $180 billion. To be clear -- I think it's highly unlikely that Nvidia will ever again be able to pump out a long consecutive string of year-over-year quarterly earnings growth in the very high double-digit to triple-digit percentages. But I don't think it has to do that in order to deliver stellar returns to investors for some time. Year-over-year earnings growth solidly in the double-digits plus a reasonable stock valuation should be all that's needed to keep investors very happy. What makes me have confidence in the "reasonable valuation" bit? Currently, Nvidia stock's valuation is reasonable by just about every measure, but that has not always been true. (For reference, it's trading at 25.4 times Wall Street's projected forward earnings per share, or EPS, as of June 18. That's an attractive valuation for a company that analysts expect will grow EPS at an average annual rate of 30% over the next five years.) The main reason I think the valuation will likely remain relatively reasonable (at least much of the time) for a while circles back to that law of large numbers. Wall Street analysts and many investors are well aware of this phenomenon, and I think most folks in both those groups will tend to continue to significantly underestimate Nvidia's future earnings growth potential due to thoughts like these: An investor and analyst thought: It's so massive, there's no way it can keep growing earnings much. An investor thought: After its massive run-up, I've missed my chance to buy Nvidia stock. (How many of us thought that about, say, Amazon many years ago, only to be proven wrong?) Consistent beliefs like these will help keep Nvidia stock's valuation reasonable in part because Wall Street analysts are going to tend to be too conservative in their estimates, in my view. Moreover, some investors will probably feel that Wall Street is being too liberal in their estimates because they themselves feel cautious given Nvidia's humongous size. Yes, this caution among many investors would likely slow down Nvidia stock's rise, but that's better than the stock frequently shooting up to unsustainable levels, only to plunge back down to Earth, in my opinion. This topic could be several articles, so here's just a brief list. 1. The company's now-annual cadence of launching new graphics processing unit (GPU) architectures for its products for its AI-accelerated data center, gaming, and other market platforms. Blackwell is its current architecture. 2. The approach of the widespread legalization of autonomous vehicles. Nvidia's GPUs will be the "brains" inside many of these vehicles. 3. The approach of the era of humanoid robots. Nvidia's GPUs will be the "brains" inside many of these robots. 4. The company will stay ahead of the innovation pack by entering emerging new technologies via organic growth and acquisitions. An example here is quantum computing, in which I think Nvidia will be increasingly involved. Before you buy stock in Nvidia, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Nvidia wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $659,171!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $891,722!* Now, it's worth noting Stock Advisor's total average return is 995% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Beth McKenna has positions in Nvidia. The Motley Fool has positions in and recommends Amazon, Microsoft, and Nvidia. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy. Could the "Next Nvidia Stock" Actually Be... Nvidia Stock? was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Yahoo

38 minutes ago

• Yahoo

Is Textron Stock Underperforming the Nasdaq?

Valued at a market cap of $13.8 billion, Textron Inc. (TXT) is a multi-industry company that leverages its global network of aircraft, defense, industrial, and finance businesses to provide customers with various solutions and services. The Providence, Rhode Island-located company operates in six segments: Textron Aviation, Bell, Textron Systems, Industrial, Textron eAviation, and Finance. Companies valued at $10 billion or more are generally classified as 'large-cap' stocks, and Textron fits this description perfectly. The company owns well-known brands like Bell Helicopters, Cessna, and Beechcraft aircraft, and Textron Systems. Dear Tesla Stock Fans, Mark Your Calendars for June 30 3 ETFs with Dividend Yields of 12% or Higher for Your Income Portfolio Nvidia Is Quickly Approaching a New Record High. Is It Too Late to Buy NVDA Stock? Markets move fast. Keep up by reading our FREE midday Barchart Brief newsletter for exclusive charts, analysis, and headlines. Textron stock has declined 19% from its 52-week high of $94.57. TXT stock has risen 3.2% over the past three months, lagging behind the broader Nasdaq Composite ($NASX), which increased 11.7% during the same period. In the longer term, TXT stock has marginally increased on a YTD basis, underperforming NASX's 1.2% return. Additionally, shares of Textron have dropped 10.9% over the past 52 weeks, compared to NASX's 9.4% gain over the same period. The stock has been trading below its 200-day moving average since late October last year. However, it has climbed above its 50-day moving average since May. Textron stock rose 2.6% following the release of its strong Q1 2025 results on Apr. 24. The company reported revenue of $3.3 billion, up 5.5% from the same quarter last year, surpassing the consensus estimate. Growth was primarily led by the Bell segment, which jumped 35.2%, driven by robust performance in both military and commercial product lines. Meanwhile, its adjusted EPS came in at $1.28, up 6.7% year-over-year, exceeding analysts' expectations. TXT reaffirmed its full-year 2025 adjusted EPS guidance of $6 to $6.20. Compared to its rival, L3Harris Technologies, Inc. (LHX) has outperformed TXT stock. LHX stock has increased 11.9% over the past 52 weeks and 18.3% on a YTD basis. Despite TXT's underperformance relative to the Nasdaq, analysts are moderately optimistic about its prospects. Among the 14 analysts covering the stock, there is a consensus rating of 'Moderate Buy,' and it is currently trading below the mean price target of $86.71. On the date of publication, Sohini Mondal did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

Yahoo

41 minutes ago

• Yahoo

Tesla's $56K India Gamble: Will the Model Y Sell in a Price-Sensitive Market?

Tesla (NASDAQ:TSLA) is finally hitting the accelerator in India. After years of back-and-forth, the EV giant is opening its first showroom in Mumbai this July, followed by another in New Delhi. It's starting with the Model Yshipped straight from its Shanghai plantmarking the company's first official sales push into the world's third-largest car market. Internal documents and people familiar with the matter confirm that Tesla has also brought in Supercharger hardware, car accessories, and parts from the US, China, and the Netherlandslaying the groundwork for a broader rollout. This move follows Elon Musk's February meeting with Indian Prime Minister Narendra Modi and could signal the start of a long-term India strategy. But it won't be an easy ride. Each Model Y imported was declared at just under $32,000, but racked up over $25,000 in import duties due to India's 70% tariff on fully-built EVs. Final sticker price? North of $56,000 before tax and insurancenearly 50% more than the U.S. price post-incentives. For a market where EVs still make up just 5% of new car sales and luxury vehicles are under 2%, Tesla will need more than brand power to spark volume. Still, the company is quietly building momentum. It's securing warehouse space in Karnataka and Gurugram, boosting hiring across charging, retail, and policy teams, and sending execs from abroad to oversee showroom setup in luxury districts. The early signs point to a premium positioning play aimed at affluent Indian buyers. Whether that strategy holdsor pivotswill depend on how fast Tesla can shift from imports to local production. For now, it's a high-stakes, high-margin experiment in one of the world's fastest-growing auto markets. This article first appeared on GuruFocus.